TY - JOUR
T1 - The effect of body mass index on therapeutic response to bacterial vaginosis in pregnancy
AU - Mastrobattista, Joan M.
AU - Klebanoff, Mark A.
AU - Carey, J. Christopher
AU - Hauth, John C.
AU - MacPherson, Cora A.
AU - Ernest, J.
AU - Cotroneo, Margaret
AU - Leveno, Kenneth J.
AU - Wapner, Ronald
AU - Varner, Michael
AU - Iams, Jay D.
AU - Moawad, Atef
AU - Sibai, Baha M.
AU - Miodovnik, Menachem
AU - Dombrowski, Mitchell
AU - O'Sullivan, Mary J.
AU - VanDorsten, J. Peter
AU - Langer, Oded
PY - 2008
Y1 - 2008
N2 - Our objective was to determine the effect of body mass index (BMI) on response to bacterial vaginosis (BV) treatment. A secondary analysis was conducted of two multicenter trials of therapy for BV and Trichomonas vaginalis. Gravida were screened for BV between 8 and 22 weeks and randomized between 16 and 23 weeks to metronidazole or placebo. Of 1497 gravida with asymptomatic BV and preconceptional BMI, 738 were randomized to metronidazole; BMI was divided into categories: <25, 25 to 29.9, and ≥30. Rates of BV persistence at follow-up were compared using the Mantel-Haenszel chi square. Multiple logistic regression was used to evaluate the effect of BMI on BV persistence at follow-up, adjusting for potential confounders. No association was identified between BMI and BV rate at follow-up (p = 0.21). BMI was associated with maternal age, smoking, marital status, and black race. Compared with women with BMI of <25, adjusted odds ratio (OR) of BV at follow-up were BMI 25 to 29.9: OR, 0.66, 95% CI 0.43 to 1.02; BMI ≥30: OR, 0.83, 95% CI 0.54 to 1.26. We concluded that the persistence of BV after treatment was not related to BMI.
AB - Our objective was to determine the effect of body mass index (BMI) on response to bacterial vaginosis (BV) treatment. A secondary analysis was conducted of two multicenter trials of therapy for BV and Trichomonas vaginalis. Gravida were screened for BV between 8 and 22 weeks and randomized between 16 and 23 weeks to metronidazole or placebo. Of 1497 gravida with asymptomatic BV and preconceptional BMI, 738 were randomized to metronidazole; BMI was divided into categories: <25, 25 to 29.9, and ≥30. Rates of BV persistence at follow-up were compared using the Mantel-Haenszel chi square. Multiple logistic regression was used to evaluate the effect of BMI on BV persistence at follow-up, adjusting for potential confounders. No association was identified between BMI and BV rate at follow-up (p = 0.21). BMI was associated with maternal age, smoking, marital status, and black race. Compared with women with BMI of <25, adjusted odds ratio (OR) of BV at follow-up were BMI 25 to 29.9: OR, 0.66, 95% CI 0.43 to 1.02; BMI ≥30: OR, 0.83, 95% CI 0.54 to 1.26. We concluded that the persistence of BV after treatment was not related to BMI.
KW - Bacterial vaginosis
KW - Body mass index
KW - Pregnancy
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=46349111107&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46349111107&partnerID=8YFLogxK
U2 - 10.1055/s-2008-1066875
DO - 10.1055/s-2008-1066875
M3 - Article
C2 - 18548397
AN - SCOPUS:46349111107
SN - 0735-1631
VL - 25
SP - 233
EP - 237
JO - American Journal of Perinatology
JF - American Journal of Perinatology
IS - 4
ER -